CORRESPONDENCE Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron Emma K. Accorsi, Amadea Britton, Nong Shang, et al N Engl J Med May 25, 2022DOI: 10.1056/NEJMc2203165 TO THE EDITOR: For persons who received a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson–Janssen) against coronavirus disease 2019 (Covid-19), a booster dose of a messenger RNA (mRNA) vaccine at least 2 months after the primary dose is recommended. R...

ARTICLES|ONLINE FIRST Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis Nicolò Girometti, Ruth Byrne, Margherita Bracchi, et al Lancet Infect Dis Published: July 01, 2022 DOI:https://doi.org/10.1016/S1473-3099(22)00411-X Summary Background Historically, human monkeypox virus cases in the UK have been limited to imported infections f...

Original Investigation May 17, 2022 Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis: A Randomized Clinical Trial The UK TAVI Trial Investigators JAMA. 2022;327(19):1875-1887. doi:10.1001/jama.2022.5776 Key Points Question  Is transcatheter aortic valve implantation (TAVI) noninferior to surgical aortic valve replacement (surgery) in patien...

ORIGINAL ARTICLEFREE PREVIEW Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A Margareth C. Ozelo, Johnny Mahlangu, K. John Pasi, et al N Engl J Med 2022; 386:1013-1025DOI: 10.1056/NEJMoa2113708 Abstract BACKGROUND Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5 (AAV5)–based gene-therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-selective promoter. The efficacy and safety of the...

ORIGINAL ARTICLE FREE PREVIEW Tranexamic Acid in Patients Undergoing Noncardiac Surgery P.J. Devereaux, Maura Marcucci, Thomas W. Painter, et al N Engl J Med 2022; 386:1986-1997DOI: 10.1056/NEJMoa2201171 Abstract BACKGROUND Perioperative bleeding is common in patients undergoing noncardiac surgery. Tranexamic acid is an antifibrinolytic drug that may safely decrease such bleeding. METHODS We conducted a trial involving patients undergoing noncardia...

Research Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study Martin Urner, Adrian G Barnett, Gianluigi Li Bassi, et al BMJ 2022; 377 doi: https://doi.org/10.1136/bmj-2021-068723 (Published 04 May 2022)Cite this as: BMJ 2022;377:e068723 Abstract Objective To estimate the effect of extracorporeal membrane oxygenation (ECMO) compared with conventional mechanical ven...

ARTICLES|ONLINE FIRST Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses WHO Solidarity Trial Consortium Lancet Published:May 02, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00519-0 Summary Background The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hyd...

ONLINE FIRST (FREE ACCESS) LATEST ARTICLES OriginalsEchocardiography findings in COVID-19 patients admitted to intensive care units: a multi-national observational study (the ECHO-COVID study)Huang S. et al. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trialBouglé A. et al.  OPEN ACCESS ~ Special issue insightEEG monitoring after cardiac arre...

OriginalOpen AccessPublished: 16 June 2022 (1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial Frank Bloos, Jürgen Held, Stefan Kluge, et al Intensive Care Med (2022). https://doi.org/10.1007/s00134-022-06733-x Abstract Purpose To investigate whether (1 → 3)-β-d-Glucan (BDG)-guidance shortens time to antifungal therapy and thereby reduces mortality of sepsis patients with high risk of invasive C...

ORIGINAL ARTICLE Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age C. Buddy Creech, Evan Anderson, Vladimir Berthaud, et al N Engl J Med May 11, 2022DOI: 10.1056/NEJMoa2203315 Abstract BACKGROUND Vaccination of children to prevent coronavirus disease 2019 (Covid-19) is an urgent public health need. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children 6 to 11 years of age are unknown. METHODS Part 1 o...